ANIX Anixa Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ANIX

Price (delayed)

$3.27

Market cap

$111.26M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.31

Enterprise value

$109.96M

?
Relative Growth: Rel. Growth: 12
Relative Strength: Rel. Strength: 54
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 10

Anixa Biosciences Inc. is a biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type ...

Highlights
ANIX's EPS is up by 18% year-on-year and by 6% since the previous quarter
The net income has increased by 17% year-on-year and by 2.7% since the previous quarter
The company's quick ratio fell by 20% QoQ but it rose by 11% YoY
The equity has contracted by 10% YoY and by 4% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.anixa.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ANIX

ANIX stock price

How has the Anixa Biosciences stock price performed over time
Intraday
4.14%
1 week
24.81%
1 month
28.24%
1 year
2.51%
YTD
4.81%
QTD
16.79%

Financial performance

How have Anixa Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$10.68M
Net income
-$10.03M
Gross margin
N/A
Net margin
N/A
ANIX's operating income is up by 19% year-on-year and by 3.2% since the previous quarter
The net income has increased by 17% year-on-year and by 2.7% since the previous quarter

Price vs fundamentals

How does ANIX's price correlate with its fundamentals

Growth

What is Anixa Biosciences's growth rate over time

Valuation

What is Anixa Biosciences stock price valuation
P/E
N/A
P/B
7.57
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ANIX's EPS is up by 18% year-on-year and by 6% since the previous quarter
The price to book (P/B) is 51% higher than the 5-year quarterly average of 5.0 and 7% higher than the last 4 quarters average of 7.1
The equity has contracted by 10% YoY and by 4% from the previous quarter

Efficiency

How efficient is Anixa Biosciences business performance
Anixa Biosciences's return on invested capital has decreased by 7% YoY
The company's return on assets fell by 4.1% YoY
The return on equity has declined by 2.2% year-on-year

Dividends

What is ANIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIX.

Financial health

How did Anixa Biosciences financials performed over time
ANIX's total liabilities is down by 21% YoY but it is up by 18% QoQ
The company's quick ratio fell by 20% QoQ but it rose by 11% YoY
The debt is 99% less than the equity
The debt has decreased by 17% YoY and by 4.7% from the previous quarter
The equity has contracted by 10% YoY and by 4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.